Previous studies have shown that naringenin can act as an Nrf activator to attenuate oxidative stress-induced hepatic injury in the liver, and also inhibits inflammation and prevents MASLD by down-regulating the NLRP3 / NF-κB pathway [7, 48]. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.